Send to

Choose Destination
Expert Rev Clin Immunol. 2014 Jun;10(6):771-80. doi: 10.1586/1744666X.2014.904747. Epub 2014 Apr 1.

Breaking the mould - novel diagnostic and therapeutic strategies for invasive pulmonary aspergillosis in the immune deficient patient.

Author information

Biosciences, University of Exeter, Geoffrey Pope Building, Exeter, EX4 4QD, UK.


Invasive pulmonary aspergillosis (IPA) caused by the ubiquitous environmental fungus Aspergillus is a frequently fatal lung disease of immunocompromised humans accounting for more than 200,000 infections each year, with an associated mortality rate of 30-90%. This review addresses the current status of IPA diagnosis and treatment and the urgent need to develop accurate, non-invasive strategies for identifying pulmonary infections in the ever-expanding population of immune deficient patients at risk of acquiring opportunistic fungal infections including hematological malignancy and hematopoetic stem cell transplant patients. Recent advances in the use of an Aspergillus-specific monoclonal antibody, JF5, for point-of-care diagnosis of IPA using lateral-flow technology is examined, as is its use in PET/MRI bioimaging and radio-immunotherapy using radionuclide-labeled single chain antibody fragments, Fab fragments, and a fully humanized JF5 derivative.


PET/MRI; bioimaging; hematological malignancy; invasive pulmonary aspergillosis; monoclonal antibody; radioimmunotherapy; stem cell transplant; vaccine

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center